Abstract
Aspartic proteases are important molecular targets for developing drugs to treat various difficult-to-treat diseases. The aspartic proteases, HIV protease and plasmepsins, are essential for the survival of the virus and malaria parasite, respectively, and AIDS and malaria are counted in two of three major infectious diseases. Renin and β-secretase that are also a class of aspartic proteases are the promising molecular targets for developing hypertension and Alzheimer's disease drugs, respectively. We have developed aspartic protease inhibitors with a transition-state analogue as drug candidates against these difficult-to-treat diseases, hypertension, AIDS, adult T-cell leukemia (ATL), human T-lymphotropic virus type I-associated myelopathy (HAM), malaria, and Alzheimer's disease. Here, we describe our recent drug discovery study on aspartic protease inhibitors.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
